ATC Group: N03AA02 Phenobarbital

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N03AA02 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N03 Antiepileptics
3 N03A Antiepileptics
4 N03AA Barbiturates and derivatives
5 N03AA02 Phenobarbital

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 0.1 g
PAREN - Parenteral 0.1 g

Active ingredients in N03AA02

Active Ingredient Description
Phenobarbital

Phenobarbital has sedative effects and has some protective action against all varieties of human partial and generalised epilepsy, with the exception of absence seizures. Phenobarbital is also effective in preventing seizures in the corresponding experimental animal models of epilepsy.

Related product monographs

Title Information Source Document Type  
SEDABARB Tablet Health Products Regulatory Authority (ZA) MPI, Generic

Medicines in this ATC group

Estonia (EE)

France (FR)

Hong Kong (HK)

Israel (IL)

Lithuania (LT)

Poland (PL)

South Africa (ZA)

Tunisia (TN)

Turkey (TR)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.